Growth Hormone

CJC-1295: What the Research Actually Shows

Last updated: April 2026

By Scott Williams·Firefighter/Paramedic · 25+ Years

Most people searching for CJC-1295 do not realize they may be looking at two different molecules with almost the same name.

That is the first thing to get straight — and honestly, it is one of the more interesting entry points in the whole GH-axis peptide category.

There is CJC-1295 with DAC, and there is CJC-1295 without DAC. Those names sound like minor product variations, but they are not. They behave differently in the body, they create different growth hormone patterns, and the community talks about them in ways that can get confusing fast.

One vendor might call something “CJC-1295 no DAC.” Another might call it “Mod GRF 1-29.” Another might just write “CJC-1295” and leave the buyer guessing.

That is not a small labeling issue. With this peptide, the name tells you what kind of growth hormone signal you are creating.

This is also the first GH-axis peptide page on Biohacking Unlocked. BPC-157, TB-500, and GHK-Cu are mostly tissue-repair stories. CJC-1295 is a different category: it is a growth-hormone-releasing peptide. The biology is genuinely interesting, and the pharmacokinetics story here is one of the more fascinating ones I have come across in this space.

Where I am stating a fact, I am citing it. Where I am sharing my read on the research, I am saying that out loud.

Verified Source

Ascension Peptides5mg

COA-verified · MZ Biolabs · US domestic

Use code BIOHACKING for 50% off your first order

Shop CJC-1295→

We only recommend vendors that pass our COA standard. How we vet →

What CJC-1295 actually is

CJC-1295 is a synthetic modified analog of GHRH — growth hormone-releasing hormone.

To understand why that matters, the basic GH axis is worth a quick sketch:

The hypothalamus releases GHRH. GHRH tells the anterior pituitary to release growth hormone. GH signals the liver and other tissues, which produce IGF-1. IGF-1 is one of the downstream signals tied to growth, repair, metabolism, and body composition.

CJC-1295 mimics GHRH. It does not bypass the pituitary the way injecting exogenous GH would. The pituitary is still in the loop. The body's own regulation is still involved. That is the part that makes GHRH analogs a pharmacologically interesting category.

Now the naming issue — because it genuinely matters:

Name	Also called	Half-life	GH pattern
CJC-1295 with DAC	DAC-GRF	6–8 days	Sustained elevation; higher trough GH
CJC-1295 without DAC	Mod GRF 1-29, Modified GRF 1-29	~30 minutes	Brief pulse, more physiological

The with-DAC version includes a Drug Affinity Complex — a maleimidopropionic acid linker that allows the molecule to bind albumin in the bloodstream. That binding dramatically extends half-life. A short-acting GHRH signal becomes something that stays pharmacologically active for nearly a week.

The result is what the community often calls a “GH bleed” — not necessarily zero pulses, but a much more sustained elevation with higher baseline GH for days after a single injection.

The without-DAC version is different. No albumin binding. Half-life of roughly 30 minutes. It produces a brief GH pulse that is closer to the way the body naturally releases GH — in peaks, not in a sustained drip.

The pharmacokinetics story here is what I find most compelling: adding one chemical modification to a peptide can stretch its half-life from 30 minutes to nearly a week. That is a real piece of drug chemistry. And it is also why the community has largely moved toward the without-DAC version — because continuous GH elevation is not how the body normally works, and shorter pulses feel more defensible as a concept.

Original developer: ConjuChem, early 2000s. Native GHRH is 44 amino acids; CJC-1295 is a 29–30 amino acid modified analog with four amino acid substitutions that resist enzymatic breakdown.

How it's supposed to work

The plain-English version: your pituitary already makes GH. CJC-1295 tells it to make more.

The mechanism is well-established. CJC-1295 binds GHRH receptors in the anterior pituitary, stimulating GH release. GH travels to the liver and other tissues, contributing to IGF-1 production. The pharmacodynamic effects — GH going up, IGF-1 going up — have been measured in human trials.

That part of the story is solid.

Here is the part worth being clear-eyed about: Stimulating GH release is measurable. Whether that translates to better body composition, faster recovery, improved sleep, or anti-aging effects in healthy adults is a much harder question — and the clinical outcomes evidence mostly has not caught up yet.

That gap — “we can measure GH moving” versus “we can prove it does what people want it to do” — is the central tension in the whole GH-axis peptide category.

What the research shows

This is where CJC-1295 actually has a more interesting story than the tissue-repair peptides.

The key study is Teichman et al. (2006) in the Journal of Clinical Endocrinology & Metabolism (PMID 16352683). This was a Phase 1 trial in approximately 50 healthy adults. Single-dose CJC-1295 with DAC produced dose-dependent mean GH increases of roughly 2- to 10-fold for six days or more, and mean IGF-1 increases of roughly 1.5- to 3-fold for 9–11 days. The estimated half-life was about 5.8–8.1 days.

That is real Phase 1 human data. A controlled study, healthy adults, measurable results.

A second important paper is Ionescu and Frohman (2006), also in JCEM (PMID 17018654), which found that CJC-1295 increased trough and mean GH secretion and IGF-1 production while GH pulsatility was preserved. The takeaway is not that pulses disappear — it is that baseline GH is elevated substantially, which changes the overall GH environment even between pulses.

That is where the pharmacology gets philosophically interesting: is sustained GH elevation for days actually what you want, or is a shorter pulse that respects the body's natural timing a better concept?

The research answers the “does it work pharmacologically” question clearly. It does. CJC-1295 moves GH and IGF-1 in humans.

What the research does not answer is whether those GH and IGF-1 changes produce the body-composition, recovery, or anti-aging outcomes people are actually looking for in healthy adults.

Safety event

A Phase II clinical trial of CJC-1295 in lipodystrophy was halted after a participant death. The relationship to the drug was investigated. FDA has also identified serious adverse events including increased heart rate and systemic vasodilatory reaction, and has noted concerns around immunogenicity and characterization of the peptide.

That belongs here. It changes the risk category for CJC-1295 compared to a tissue-repair peptide.

My read: the pharmacology story here is one of the more interesting ones on this site. The human signal is real. But the Phase 1 data proves the drug does something — it does not prove it does everything the community wants it to do.

What the community uses it for

Community-reported uses — not endorsements.

CJC-1295 shows up in biohacking and performance communities mostly for:

Body recomposition (fat loss and lean muscle)
Recovery
Sleep quality
Anti-aging
General GH optimization

The CJC-1295 + Ipamorelin Stack

The most popular use is the CJC-1295 without DAC + Ipamorelin stack, and the reasoning behind it is actually one of the more mechanistically coherent ideas in the community.

CJC-1295 without DAC hits the GHRH receptor — one GH switch. Ipamorelin hits the ghrelin receptor, also called the growth hormone secretagogue receptor — a different GH switch. Push both at the same time and you get a stronger GH pulse than either compound alone, while still preserving a pulsatile pattern rather than keeping GH elevated continuously.

That is why the stack caught on. There is at least a real biological idea behind it, not just two random peptides combined because the names sound good.

What is not there yet is human clinical outcomes research showing the stack delivers on the downstream promises — body composition, recovery, sleep quality in healthy adults.

Community-reported protocols:

Without DAC (Mod GRF 1-29): often discussed around 100 mcg, 1–3 times daily, subcutaneous, commonly paired with 100 mcg Ipamorelin in the same injection
With DAC: often discussed around 1–2 mg per week, subcutaneous
Common cycle pattern: 8–16 weeks on, followed by time off

Community protocols only. Not validated medical dosing.

Hard avoidance categories: active or recent cancer, uncontrolled diabetes, untreated sleep apnea, pregnancy or breastfeeding, and anyone under 18 or not past skeletal maturity. GH-axis manipulation raises specific concerns in all of those situations.

The regulatory situation (April 2026)

Regulatory status is the part of any peptide page that goes stale fastest, so this section is current as of April 2026.

CJC-1295 is not FDA approved for any indication.

FDA has flagged safety concerns with CJC-1295 specifically — including cardiovascular-type reactions and questions around immunogenicity and API characterization. PCAC discussions involving CJC-1295 occurred in October and December 2024.

One note on current status: the April 2026 Federal Register removals primarily covered BPC-157, TB-500, GHK-Cu injectable, Semax, Epitalon, MOTs-C, and KPV. CJC-1295's exact Category 2 status after April 2026 should be verified against the current FDA docket before publishing any hard legal claim. This page reflects the cleaner framing: CJC-1295 is not FDA approved, it has been under active FDA compounding-review scrutiny, and its regulatory status is worth checking as this space moves quickly.

WADA

WADA is much clearer. CJC-1295 is explicitly prohibited. The 2026 WADA Prohibited List names it specifically under S2.2.4 — “growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin).” Banned at all times.

That is not a gray area for tested athletes.

In the United States, CJC-1295 is sold as a research chemical. Legal to sell and possess. Not a controlled substance. But “research use only” is a legal framing, not a safety guarantee.

The purity problem

The vendor question matters with every research peptide. With CJC-1295, the naming problem becomes a direct mislabeling risk.

A vial labeled “CJC-1295” could contain the with-DAC version, the without-DAC version, or a product that does not cleanly match either. Gray-market peptide purity is inconsistent across the research-chemical space, and CJC-1295 is one of the peptides where the naming inconsistency compounds the usual quality-control concerns.

The COA question for CJC-1295 goes beyond basic purity:

Is this with DAC or without DAC?
Does the test confirm the exact sequence or modification?
Does mass spectrometry confirm the DAC modification if the product claims to have it?
Does the batch number match the vial?
Is purity confirmed by HPLC?
Is the lab real and third-party verifiable?
Are sterility and endotoxin addressed?

A COA is not decoration. It is the receipt — and for CJC-1295, the receipt needs to identify the exact molecule, not just put a purity number next to the name.

For beginners, this is where I would spend the most time before even thinking about vendor comparisons:

How to read a COA →See our vetted peptide sources →How to identify fake peptides →

My read: vendor quality is the practical bottleneck in this entire space. With CJC-1295, the naming problem means a buyer can think they ordered one molecule and receive a meaningfully different one. That is not hypothetical — it is one of the more common failure points in the gray-market peptide world.

What isn't settled yet

A few honest open questions, and my read on each:

Does GH/IGF-1 elevation in healthy adults translate to clinical benefits?
The pharmacology is established. The clinical outcomes in healthy people are not.
What are the long-term cardiovascular effects?
The Phase II event and FDA-flagged reactions mean this deserves a real answer that the current data does not fully provide.
Does the DAC version carry extra risk from sustained GH elevation?
The Ionescu paper shows pulsatility is preserved but trough GH is elevated. Whether a chronically elevated GH baseline has different long-term consequences than a pulsatile-only pattern is not established.
What happens to glucose metabolism with chronic use?
GH axis stimulation can affect insulin sensitivity. The long-term picture for healthy users is not well characterized.
Cancer risk via IGF-1?
IGF-1 elevation is associated in epidemiological research with several cancer types. That does not prove CJC-1295 causes cancer, but it is a reason the question cannot be dismissed, especially with long-term use.
Does the CJC-1295 + Ipamorelin stack produce meaningful outcomes?
The mechanistic rationale is real. Human clinical outcome data on the combination in healthy adults is not there yet.
Does with-DAC offer any practical advantage over without-DAC?
The longer half-life is measurable. Whether that translates to better outcomes compared to a more physiological short-pulse approach has not been established.

Bottom line

My honest read: CJC-1295 is one of the more pharmacologically interesting peptides I have looked at in this category.

The pharmacokinetics story alone is worth understanding — the difference between a 30-minute half-life and a 6-8-day half-life coming down to a single albumin-binding modification is genuinely fascinating drug chemistry. And unlike the tissue-repair peptides, CJC-1295 has a real Phase 1 human study showing measurable GH and IGF-1 elevation in healthy adults. That is a more direct human signal than a lot of what is in the biohacking space.

The CJC-1295 + Ipamorelin stack is one of the more coherent community ideas I have come across. Two different GH switches hit at the same time, preserving pulsatility, aiming for a synergistic GH pulse. The community worked out the mechanism before clinical research caught up — and the mechanism genuinely makes sense.

But the clinical outcomes gap is real. Moving GH and IGF-1 is step one of a long chain. Whether healthy adults actually get the body-composition, recovery, and anti-aging results they are looking for is a question the evidence has not answered yet.

The with-DAC version is the one I find more complicated conceptually. Keeping GH elevated at a higher baseline for days changes the hormonal environment in ways that are less physiological than a short pulse. The without-DAC version, the short-acting Mod GRF 1-29, is a more defensible concept — it respects the body's natural pulsing rhythm instead of overriding it.

And for athletes: CJC-1295 is named on the WADA Prohibited List. That part of the conversation is settled.

Disclaimer

This page is informational and not medical advice. Biohacking Unlocked is not a medical resource. CJC-1295 is not FDA approved for any indication, and research-use products are commonly labeled “for research purposes only / not for human consumption.” Anyone considering peptides should talk with a qualified healthcare provider. See our full disclaimer.